_EVA Pharma is committed to expanding patient access to modern treatment options, with plans for local manufacturing at its industrial complex in Sudair Industrial City, Saudi Arabia. _

Jeddah, 16 September 2026 | 5 Rabi’ Al-Thani 1448 —

EVA Pharma for Industry, one of the leading pharmaceutical companies developing, manufacturing and providing medicines across the Middle East and Africa, and Cigalah Healthcare Company, one of Saudi Arabia’s leading companies in healthcare distribution and biomedical solutions, have strengthened their existing partnership to distribute TriGutirek XR® extended-release (Empagliflozin / Linagliptin / Metformin Hydrochloride) in the Kingdom of Saudi Arabia. TriGutirek XR® is the first fixed-dose combination tablet containing these three active ingredients to be approved in Saudi Arabia for the management of type 2 diabetes, in accordance with the product’s approved medical and regulatory information.

EVA Pharma will prioritize the local manufacturing of TriGutirek XR® at its research and manufacturing complex in Sudair. This comes as part of the announced plans for the industrial complex, set to localize 150 medicines in the Kingdom, contributing to Saudi Arabia’s priorities in pharmaceutical localization, pharmaceutical security and self-sufficiency in line with Vision 2030.

Dr. Riad Armanious, CEO of EVA Pharma, said: “At the heart of every responsible pharmaceutical system is the patient. That is why we are establishing pharmaceutical capabilities that bring together scientific research, local manufacturing, quality and reliable supply chain, aligned with the priorities and institutions of the Kingdom of Saudi Arabia. Our longstanding partnership with Cigalah Healthcare Company puts this commitment into practice by supporting patient access to innovative and approved treatment options.”

Yaser Yousef Naghi, CEO of Cigalah Healthcare Company, said: “Our partnership with EVA Pharma is built on a shared commitment to supporting the availability of approved treatment options that respond to the needs of the healthcare sector in the Kingdom. We consider strengthening this agreement by adding new treatments to the Saudi market an important step in supporting the healthcare system’s efforts to raise the standard of care by ensuring the availability of such modern medicines in Saudi Arabia.”

The agreement was signed in Jeddah in the presence of Mr. Yaser Yousef Naghi, CEO of Cigalah Healthcare Company, and Dr. Riad Armanious, CEO of EVA Pharma, on the sidelines of the Saudi Industrial Forum. The agreement strengthens a partnership between the two companies that dates back to 2008 and reaffirms their continued cooperation in supporting access to approved treatment options for patients through healthcare channels across the Kingdom, in accordance with applicable regulatory requirements.

ENDS About EVA Pharma for Industry

EVA Pharma for Industry is a subsidiary of EVA Pharma Holdings, one of the fastest-growing healthcare companies in the Middle East and Africa. EVA Pharma for Industry is registered in the Kingdom of Saudi Arabia as a local pharmaceutical manufacturer with a focus on sustainability and local investment in the Kingdom.

EVA Pharma is dedicated to improving access to affordable, high-quality medicines around the world, focusing on three core pillars: innovation, development and sustainable access. The company leverages cutting-edge technology at two research centers bringing first-of-its-kind capabilities to the Middle East and Africa including mRNA research and development from AI prediction to biological products.

With a 5,000-strong team of professionals, EVA Pharma produces more than one million healthcare products a day at four state-of-the-art manufacturing facilities, which are internationally recognized for innovation, and have been approved by multiple regulatory agencies.

Guided by a relentless drive to ensure sustainable access to pressing yet unmet disease areas, the company’s product portfolio focuses on twelve therapeutic areas: Anti-infectives, metabolic health, bone, neuroscience, oncology, respiratory, gynecology, urology and andrology, pediatrics, ophthalmology, gastrointestinal tract, family medicine to meet both local and international demand. 

For more information, please visit: evapharma.com & evapharma.com/newsroom or follow us on X, LinkedIn & Instagram   About Cigalah Healthcare Company

Cigalah Healthcare Company is one of Saudi Arabia’s leading healthcare companies, with a well-established presence and a distribution network spanning the Kingdom, alongside a growing presence in Gulf Cooperation Council markets.

Over the decades, the company has contributed to the provision of healthcare in the Kingdom through long-standing partnerships with a number of international companies and by providing a broad range of medicines, products and healthcare solutions.

Its activities span pharmaceuticals, medical devices and supplies, and healthcare products. Through its specialized business divisions, the company serves both the public and private sectors, including hospitals, healthcare authorities, pharmacies and healthcare providers.

Cigalah Healthcare Company’s strategy is built on developing sustainable partnerships with international companies, strengthening its local capabilities, and contributing to the availability of modern and reliable healthcare products and solutions in the Saudi market.

The company continues to develop its businesses and investments in line with the needs of Saudi Arabia’s healthcare sector and the objectives of Vision 2030, contributing to the localization of the sector and strengthening its long-term capabilities.